Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – April 22, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce the signing of a wide-scope commercial distribution agreement with Polyflame Europe.
As part of the multi-year agreement, Polyflame Europe will enjoy an exclusive right to distribute both of Innocan’s SHIR and Relief & Go brands in France based on a purchase forecast of 600,000 [EUR] per year in the first year and subject to suitable regulation in France.
Polyflame built its reputation as a key European player in the import and distribution of regulated products. They have been very active in Europe for the past 48 years, positioning them as one of the major players in their industry.
Some analysts report that the global CBD skin care market is expected to reach USD 1.7 billion by 2025, according to Million Insights. Innocan Pharma and SHIR will now be stepping-up to become market leaders in many European countries including France, with CBD-infused products as the power-house of the market.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81238
Powered by WPeMatico
